bleeding

Blush reduction in a not responsible vessel is a prognostic marker in those receiving angioplasty in the culprit vessel.

Original title: Impact of Nonculprit Vessel Myocardial Perfusion on Outcomes of Patients Undergoing Percutaneos Coronary OIntervention for Acute Coronary Síndromes. Analysis From ACUITY Trial. Reference: Alexandra Lansky, et al. JAAC Cardiovascular Intervention 2014,7:266-275 In Non ST elevation Acute Coronary Syndrome (NSTE-ACS) is demonstrated that revascularization of the culprit vessel is beneficial, but strategy it is not yet clear...

Higher event rate in those with non-ST elevation ACS who received revascularization at PLATO study. Beyond this, ticagrelor reduced mortality.

Original title: Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Reference: Lindholm D et al. Eur Heart J. 2014; Epub ahead of print. The PLATO study randomized 18624 patients with ACS to aspirin and ticagrelor (180 mg loading dose followed by 90 mg every 12 hours) versus...

TVAR live edited broadcasts are safe.

Original title: The impact of live transmition on patients outcomes during transcatheter aortic valve replacement: Results fron the VERITAS study. Reference: Ron Waskman, et al. Cardiovascular Revascularization Medicine 2014;15:63-68   With the advancement of medical technology and the great development of telecommunications, performing live or edited cases has become a common occurrence in medical education, but one of...

Core Valve in high-risk patients, superior to surgical replacement at one year

Original title: Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. Reference: David H. Adams et al. N Engl J Med. 2014 Mar 29. [Epub ahead of print]. Transcatheter Aortic valve replacement (TAVR) with balloon expandable valve showed survival improvement in inoperable patients and was similar to surgery inoperable high-risk patients. An alternative to the above device is the self-expandable...

Deferred Stenting in Primary Angioplasty could reduce No Reflow Risk and Infarct Size.

Original: A Randomized Trial of Deferred Stenting versus Immediate Stenting to Prevent No-or Slow Reflow in Acute ST-Elevation Myocardial Infarction (DEFER-STEMI). Reference: David Carrick et al. J Am Coll Cardiol. 2014. Epub ahead of print. No Reflow physiopathology involves microvascular obstruction secondary to thrombus embolization, spasm or microvascular thrombosis, and happens in approximately 10% of PCI procedures. The...

Prophylactic vena cava filters in trauma patients effectively reduces pulmonary embolism

Original title: The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. Reference: Haut ER et al. JAMA Surg. 2014;149:194-202. Trauma is one of the strongest risk factors for pulmonary embolism (PE). Current guidelines recommend low molecular weight heparin therapy which have been proved effective; however, trauma patients often present high risk...

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following Resolute zotarolimus-eluting stent implantation. Reference: Silber S, Kirtane AJ, Belardi JA, et al. Eur Heart J. 2014; Epub ahead of print. Dual antiplatelet aggregation optimal time after implantation of a new generation drug-eluting stent (DES) is still discussed. This...

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Original title: In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome. Reference: Dimitrios Alexopoulos et al. Am Heart J 2014;167:68-76.e2. Given the availability of 3 Oral P2Y12 receptor inhibitors (clopidogrel, prasugrel, and ticagrelor) with different safety and efficacy profiles, the change from one to another...

Stent reestenosis, the only subgroup that benefits from longer double antiaggregation

Original title: Short vs. Long Term Duration of Dual Antiplatelet Therapy in Patients treated for InstentRestenosis. A PRODIGY Trial substudy. Reference: Gianluca Campo el al. J Am CollCardiol, article in press.   In the study PRODIGY (Prolonging Dual Antiplatelet Treatment After Grading Stent- Induced Intimal Hyperplasia) we found that the 24 months ratio of dual antiaggregation was not...

TAVI: emergency surgery is rare

Original title: Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): insight from Edwards SAPIENS Aortic Bioprótesis European Outcome (SOURCE) registry Reference: Holger Eggebrecht, et; al. Eurointervention 2013; 9online publish-ahead of print november 2013 Percutaneous aortic valve implantation has grown significantly since its inception, to be a safe procedure. The need for emergency cardiac surgery is rare, its...

Top